Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19977078 | 0.79 | DYRK1A (0.45) | MEN1KMT2A | |
| SCHEMBL9442047 | 0.74 | KDM4E (0.47) | MAPK1KDM4EALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL6755827 | 0.73 | KDM4E (0.57) | MAPK1KDM4EALDH1A1PKMSMN1; SMN2 | |
| Butyric Acid SCHEMBL28289188 | 0.73 | MAPK1 (0.49) | MAPK1KDM4EALDH1A1 | |
| SCHEMBL10725199 | 0.71 | KDM4E (0.47) | KDM4EALDH1A1PKMSMN1; SMN2KMT2A | |
| SCHEMBL27986966 | 0.71 | KDM4E (0.47) | MAPK1KDM4EALDH1A1PKMSMN1; SMN2 | |
| SCHEMBL15330740 | 0.71 | KDM4E (0.47) | MAPK1KDM4EALDH1A1PKMTSHR | |
| SCHEMBL9442051 | 0.70 | MAPK1 (0.45) | MAPK1KDM4EALDH1A1NPC1MEN1 | |
| SCHEMBL438493 | 0.69 | KDM4E (0.46) | KDM4EALDH1A1PKM | |
| SCHEMBL1491103 | 0.69 | ALDH1A1 (0.49) | KDM4EALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512604-B1 | STABLE YELLOW IMIDAZOLIUM COMPOUNDS AND METHODS FOR THEIR USE | WELLA OPERATIONS US LLC (US) | 2023-05-31 | — | — | EP | disclosed |
| EP-3512604-A1 | STABLE YELLOW IMIDAZOLIUM COMPOUNDS AND METHODS FOR THEIR USE | Noxell Corporation (US) | 2019-07-24 | — | — | EP | disclosed |
| US-10093807-B2 | Stable yellow imidazolium compounds | NOXELL CORPORATION (US) | 2018-10-09 | — | — | US | disclosed |
| WO-2018053027-A1 | STABLE YELLOW IMIDAZOLIUM COMPOUNDS AND METHODS FOR THEIR USE | NOXELL CORPORATION (US) | 2018-03-22 | — | — | WO | disclosed |
| US-20180079907-A1 | Stable Yellow Imidazolium Compounds | WELLA OPERATIONS US, LLC | 2018-03-22 | — | — | US | disclosed |
| US-20180078477-A1 | Method of Coloring Hair with Washfast Yellow Imidazolium Direct Dye Compounds | WELLA OPERATIONS US, LLC | 2018-03-22 | — | — | US | disclosed |
| US-9918919-B1 | Method of coloring hair with washfast yellow imidazolium direct dye compounds | NOXELL CORPORATION (US) | 2018-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180078477-A1 | Method of Coloring Hair with Washfast Yellow Imidazolium Direct Dye Compounds | WASHC4, TYR, WASHC5 | MAPK1 968/4885KDM4E 637/4885ALDH1A1 228/4885 |
| US-10093807-B2 | Stable yellow imidazolium compounds | IK, NDUFV1, NDUFV2 | MAPK1 2839/4885KDM4E 2746/4885ALDH1A1 1345/4885 |
| US-20180079907-A1 | Stable Yellow Imidazolium Compounds | IK, NDUFV1, NDUFV2 | MAPK1 2839/4885KDM4E 2746/4885ALDH1A1 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.